Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval crawled time : 08:00 save search
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
Apollo Adds ELTIF to Wealth Product Platform Following CSSF Regulatory Approval
Published: 2023-12-11 (Crawled : 08:00) - globenewswire.com
APO | $112.72 -0.92% -1.53% 1.4M
|
Finance
|
| O: 0.2%
H: 0.86%
C: -0.36%
approval platform
Nigerian Breweries seeks shareholders’ approval for Distell’s acquisition – Businessday
Published: 2023-11-22 (Crawled : 08:00) - spacfeed.com
CLAY 4 | $10.66 3.47% 9.2K
|
|
| O: 0.54%
H: 0.0%
C: 0.0%
approval acquisition
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 08:00) - biospace.com/
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 2.58%
H: 0.08%
C: -3.42%
nefecon nephropathy drug approval treatment application
Sienna Receives BLM Approval for Drill Permit For Up to 5 Initial Locations on the “Elko Lithium Project” in Elko County, Nevada Bordering Surge Battery Metals
Published: 2023-10-06 (Crawled : 08:00) - siennaresources.com
SNNAF | $0.025 262.5% 1K
|
Non-Energy Minerals
|
| O: 3.65%
H: 0.98%
C: 0.98%
SLB A | $49.11 -0.89% -0.06% 10M
|
Industrial Services
|
| O: 0.32%
H: 1.15%
C: 0.22%
ALB | News | $115.27 0.93% -0.23% 2.2M
|
Process Industries
|
| O: -0.24%
H: 4.21%
C: 3.35%
TSLA | News | $162.11 12.05% 10.13% 180M
|
Consumer Durables
|
| O: -2.33%
H: 3.02%
C: 2.58%
lithium approval battery
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Published: 2023-09-25 (Crawled : 08:00) - globenewswire.com
ALVO | $13.5 0.75% 0.74% 190K
|
n/a
|
| O: 1.24%
H: 4.25%
C: -0.67%
KMDA | $5.16 1.18% 1.16% 11K
|
Health Technology
|
| O: 1.16%
H: 1.98%
C: -0.38%
avt04 stelara biosimilar japan approval
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
Published: 2023-09-21 (Crawled : 08:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: -4.58%
H: 4.8%
C: 1.2%
fda approval meeting
FG ACQUISITION CORP. ANNOUNCES SHAREHOLDER APPROVAL OF ALL RESOLUTIONS IN CONNECTION WITH ITS QUALIFYING ACQUISITION – Yahoo Finance
Published: 2023-06-29 (Crawled : 08:00) - spacfeed.com
GAXY | $0.0001 0.0% 340K
|
Information
|
| O: 0.0%
H: 25.0%
C: 25.0%
approval acquisition
Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich’s Ataxia
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 6.1%
H: 5.34%
C: 0.82%
skyclarys approval pharmaceuticals commercial
Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWSTTM (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI
Published: 2023-04-27 (Crawled : 08:00) - biospace.com/
MCRB | $0.7295 -4.01% -4.18% 5.8M
|
Health Technology
|
| O: 3.12%
H: 0.76%
C: -19.39%
fda antibacterial health approval infection treatment therapeutics
Bioprojet: WAKIX® (pitolisant) receives approval for the treatment of narcolepsy in children over 6 years of age, a rare, under-diagnosed condition
Published: 2023-03-15 (Crawled : 08:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -10.84%
H: 0.0%
C: 0.0%
wakix treatment children narcolepsy approval
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer
Published: 2023-02-10 (Crawled : 08:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -2.43%
H: 0.66%
C: 0.66%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -1.07%
H: 0.06%
C: -0.55%
ANAB | $19.25 0.37% 0.36% 390K
|
Health Technology
|
| O: 0.04%
H: 1.27%
C: -0.62%
treatment fda grants approval cancer
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
Published: 2022-11-23 (Crawled : 08:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.1%
H: 0.62%
C: -0.35%
skyrizi treatment disease active approval
Press Release: European Commission grants first approval worldwide of Beyfortus® (nirsevimab) for prevention of RSV disease in infants
Published: 2022-11-04 (Crawled : 08:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
beyfortus disease grants approval
InnoCare Announces Approval to Conduct a Phase II Clinical Trial of Tafasitamab in Combination with Lenalidomide in China
Published: 2022-05-26 (Crawled : 08:00) - biospace.com/
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
MOR | News | $18.07 0.17% 0.17% 130K
|
Health Technology
|
| O: 3.5%
H: 2.14%
C: 0.19%
trial approval china
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
Published: 2022-01-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval system therapy
BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT® (Siltuximab for Injection) in China for Idiopathic Multicentric Castleman Disease
Published: 2021-12-03 (Crawled : 08:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K
|
Health Technology
|
| O: -0.98%
H: 0.0%
C: 0.0%
ema approval disease china injection
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
Published: 2021-11-29 (Crawled : 08:00) - biospace.com/
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -4.74%
H: 1.86%
C: 1.05%
QGEN | $41.52 -0.88% 0.0% 820K
|
Health Technology
|
| O: -4.74%
H: 1.86%
C: 1.05%
quantiferon fda fda approval test approval
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy
Published: 2021-09-09 (Crawled : 08:00) - globenewswire.com
RARE F | $44.26 -1.88% -1.92% 670K
|
Health Technology
|
| O: -0.58%
H: 2.56%
C: -0.46%
media treatment approval
Medivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818
Published: 2021-08-31 (Crawled : 08:00) - prnewswire.com
IGMS | $7.95 3.25% 3.14% 690K
|
Health Technology
|
| O: 0.37%
H: 1.35%
C: -2.63%
phase 1 approval phase 2 phase 3
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.